EP0434765B1
(de)
*
|
1988-09-30 |
1995-11-08 |
Neorx Corporation |
Wässrige additivsysteme, verfahren und polymerteilchen
|
US5066789A
(en)
*
|
1988-09-30 |
1991-11-19 |
Neorx Corporation |
Targeting substance-diagnostic/therapeutic agent conjugates having Schiff base linkages
|
US5576288A
(en)
*
|
1989-04-27 |
1996-11-19 |
The Salk Institute For Biological Studies |
Fibroblast growth factor conjugates
|
US5672683A
(en)
*
|
1989-09-07 |
1997-09-30 |
Alkermes, Inc. |
Transferrin neuropharmaceutical agent fusion protein
|
US5182107A
(en)
*
|
1989-09-07 |
1993-01-26 |
Alkermes, Inc. |
Transferrin receptor specific antibody-neuropharmaceutical or diagnostic agent conjugates
|
US5977307A
(en)
*
|
1989-09-07 |
1999-11-02 |
Alkermes, Inc. |
Transferrin receptor specific ligand-neuropharmaceutical agent fusion proteins
|
US6329508B1
(en)
|
1989-09-07 |
2001-12-11 |
Alkermes, Inc. |
Transferrin receptor reactive chimeric antibodies
|
US5527527A
(en)
*
|
1989-09-07 |
1996-06-18 |
Alkermes, Inc. |
Transferrin receptor specific antibody-neuropharmaceutical agent conjugates
|
US5154924A
(en)
*
|
1989-09-07 |
1992-10-13 |
Alkermes, Inc. |
Transferrin receptor specific antibody-neuropharmaceutical agent conjugates
|
US6610299B1
(en)
|
1989-10-19 |
2003-08-26 |
Aventis Pharma Deutschland Gmbh |
Glycosyl-etoposide prodrugs, a process for preparation thereof and the use thereof in combination with functionalized tumor-specific enzyme conjugates
|
US7241595B2
(en)
*
|
1989-10-20 |
2007-07-10 |
Sanofi-Aventis Pharma Deutschland Gmbh |
Glycosyl-etoposide prodrugs, a process for preparation thereof and the use thereof in combination with functionalized tumor-specific enzyme conjugates
|
US6475486B1
(en)
|
1990-10-18 |
2002-11-05 |
Aventis Pharma Deutschland Gmbh |
Glycosyl-etoposide prodrugs, a process for preparation thereof and the use thereof in combination with functionalized tumor-specific enzyme conjugates
|
US5137877B1
(en)
*
|
1990-05-14 |
1996-01-30 |
Bristol Myers Squibb Co |
Bifunctional linking compounds conjugates and methods for their production
|
GB9017024D0
(en)
*
|
1990-08-03 |
1990-09-19 |
Erba Carlo Spa |
New linker for bioactive agents
|
CA2048089A1
(en)
*
|
1990-09-17 |
1992-03-18 |
Wolfgang A. Wrasidlo |
Chemical conjugation of morpholino anthracyclines to antibodies
|
GB9026491D0
(en)
*
|
1990-12-05 |
1991-01-23 |
Erba Carlo Spa |
Anthracycline-conjugates
|
US5776458A
(en)
*
|
1990-12-05 |
1998-07-07 |
Pharmacia & Upjohn S.P.A. |
Anthracycline-conjugates
|
US5272253A
(en)
*
|
1991-07-01 |
1993-12-21 |
Eli Lilly And Company |
Cluster conjugates of drugs with antibodies
|
US5622929A
(en)
*
|
1992-01-23 |
1997-04-22 |
Bristol-Myers Squibb Company |
Thioether conjugates
|
US5505931A
(en)
*
|
1993-03-04 |
1996-04-09 |
The Dow Chemical Company |
Acid cleavable compounds, their preparation and use as bifunctional acid-labile crosslinking agents
|
GR1001459B
(el)
*
|
1992-10-08 |
1993-12-30 |
Lilly Co Eli |
Σύμπλεγμα συζυγών φαρμάκων με αντισώματα.
|
DE4236237A1
(de)
*
|
1992-10-27 |
1994-04-28 |
Behringwerke Ag |
Prodrugs, ihre Herstellung und Verwendung als Arzneimittel
|
US5556623A
(en)
*
|
1993-03-30 |
1996-09-17 |
Eli Lilly And Company |
Antibody-drug conjugates
|
US6551618B2
(en)
|
1994-03-15 |
2003-04-22 |
University Of Birmingham |
Compositions and methods for delivery of agents for neuronal regeneration and survival
|
DE4435087A1
(de)
*
|
1994-09-30 |
1996-04-04 |
Deutsches Krebsforsch |
Konjugat zur Behandlung von Infektions-, Autoimmun- und Hauterkrankungen
|
US6015555A
(en)
*
|
1995-05-19 |
2000-01-18 |
Alkermes, Inc. |
Transferrin receptor specific antibody-neuropharmaceutical or diagnostic agent conjugates
|
US20030119724A1
(en)
*
|
1995-11-22 |
2003-06-26 |
Ts`O Paul O.P. |
Ligands to enhance cellular uptake of biomolecules
|
US5843903A
(en)
*
|
1995-11-27 |
1998-12-01 |
The Administrators Of The Tulane Educational Fund |
Targeted cytotoxic anthracycline analogs
|
DE69626849T2
(de)
*
|
1995-12-22 |
2003-12-24 |
Bristol Myers Squibb Co |
Verzweigte hydrazongruppen enthaltende kuppler
|
EP0941120A4
(de)
*
|
1996-11-05 |
2004-08-18 |
Bristol Myers Squibb Co |
Verzweigte peptidlinker
|
US6759509B1
(en)
|
1996-11-05 |
2004-07-06 |
Bristol-Myers Squibb Company |
Branched peptide linkers
|
CA2248592A1
(en)
|
1998-08-31 |
2000-02-29 |
Christopher D. Batich |
Microspheres for use in the treatment of cancer
|
GB9917012D0
(en)
*
|
1999-07-20 |
1999-09-22 |
Pharmacia & Upjohn Spa |
Combined preparations comprising antitumor agents
|
US20060014684A1
(en)
*
|
2000-03-03 |
2006-01-19 |
University Technologies International Inc. |
Novel uses of EGF
|
US6586207B2
(en)
|
2000-05-26 |
2003-07-01 |
California Institute Of Technology |
Overexpression of aminoacyl-tRNA synthetases for efficient production of engineered proteins containing amino acid analogues
|
US7115573B2
(en)
*
|
2000-06-14 |
2006-10-03 |
Medarex, Inc. |
Prodrug compounds with an isoleucine
|
US6624317B1
(en)
|
2000-09-25 |
2003-09-23 |
The University Of North Carolina At Chapel Hill |
Taxoid conjugates as antimitotic and antitumor agents
|
EP1355672A2
(de)
|
2000-12-01 |
2003-10-29 |
Cell Works Inc. |
"konjugate von glykosylierten/galaktosylierten peptiden, bifunktionellen linkern und nukleotid?monomeren/polymeren, damit zusammenhängende zusammensetzungen, sowie verfahren zu ihrer verwendung"
|
WO2002049672A2
(en)
*
|
2000-12-21 |
2002-06-27 |
Mcgill University |
Conjugates of antibodies and anticancer drugs
|
US7445802B2
(en)
*
|
2000-12-26 |
2008-11-04 |
Yeda Research And Development Co. Ltd |
Site-specific in situ generation of allicin using a targeted alliinase delivery system for the treatment of cancers, tumors, infectious diseases and other allicin-sensitive diseases
|
US7829084B2
(en)
*
|
2001-01-17 |
2010-11-09 |
Trubion Pharmaceuticals, Inc. |
Binding constructs and methods for use thereof
|
US7754208B2
(en)
|
2001-01-17 |
2010-07-13 |
Trubion Pharmaceuticals, Inc. |
Binding domain-immunoglobulin fusion proteins
|
US20100056762A1
(en)
|
2001-05-11 |
2010-03-04 |
Old Lloyd J |
Specific binding proteins and uses thereof
|
US7589180B2
(en)
|
2001-05-11 |
2009-09-15 |
Abbott Laboratories Inc. |
Specific binding proteins and uses thereof
|
PL367244A1
(en)
*
|
2001-05-15 |
2005-02-21 |
Faulk Pharmaceuticals, Inc. |
Targeted delivery of drugs for the treatment of viral infections
|
EP1441754A1
(de)
*
|
2001-10-26 |
2004-08-04 |
University Technologies International Inc. |
Verwendung von egf zur behandlung von pathogeninfektionen des urogenitalstraktes
|
RU2196604C1
(ru)
*
|
2001-12-21 |
2003-01-20 |
Северин Евгений Сергеевич |
Полипептид, являющийся аналогом рецепторсвязывающего фрагмента эпидермального фактора роста с 21-й по 31-ю аминокислоту, его конъюгат с доксорубицином и фармацевтическая композиция на его основе
|
US9770517B2
(en)
|
2002-03-01 |
2017-09-26 |
Immunomedics, Inc. |
Anti-Trop-2 antibody-drug conjugates and uses thereof
|
ATE516818T1
(de)
|
2002-07-31 |
2011-08-15 |
Seattle Genetics Inc |
Auristatin-konjugate und ihre verwendung zur behandlung von krebs, einer autoimmunkranheit oder einer infektionskrankheit
|
EP1572242B1
(de)
*
|
2002-12-13 |
2014-04-16 |
Immunomedics, Inc. |
Immun-conjugate mit einem intrazellular spaltbaren linker
|
WO2004073656A2
(en)
|
2003-02-20 |
2004-09-02 |
Seattle Genetics, Inc. |
Anti-cd70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders
|
US20040171175A1
(en)
*
|
2003-02-28 |
2004-09-02 |
Swanson Basil I. |
Process for conjugating biomolecules to hydrophobic membrane-incorporated molecules
|
US20040219103A1
(en)
*
|
2003-05-02 |
2004-11-04 |
Jasbir Sandhu |
Methods useful for the diagnosis, imaging and treatment of tumors
|
US20040220085A1
(en)
*
|
2003-05-02 |
2004-11-04 |
Jasbir Sandhu |
Compositions for nucleic acid delivery
|
US20040219097A1
(en)
*
|
2003-05-02 |
2004-11-04 |
Jasbir Sandhu |
Composition useful for the diagnosis, imaging and treatment of tumors
|
US20040220390A1
(en)
*
|
2003-05-02 |
2004-11-04 |
Jasbir Sandhu |
Composition useful for the treatment of tumors
|
US20040219101A1
(en)
*
|
2003-05-02 |
2004-11-04 |
Jasbir Sandhu |
Composition useful for treatment of tumors
|
US20040220121A1
(en)
*
|
2003-05-02 |
2004-11-04 |
Jasbir Sandhu |
Methods for drug delivery
|
US20040219104A1
(en)
*
|
2003-05-02 |
2004-11-04 |
Jasbir Sandhu |
Methods for treatment of tumors
|
US20040219100A1
(en)
*
|
2003-05-02 |
2004-11-04 |
Jasbir Sandhu |
Composition useful for the treatment of tumors
|
US20040219099A1
(en)
*
|
2003-05-02 |
2004-11-04 |
Jasbir Sandhu |
Method for the treatment of tumors
|
US20040220084A1
(en)
*
|
2003-05-02 |
2004-11-04 |
Jasbir Sandhu |
Methods for nucleic acid delivery
|
US20040219102A1
(en)
*
|
2003-05-02 |
2004-11-04 |
Jasbir Sandhu |
Compositions for drug delivery
|
US9011880B2
(en)
*
|
2003-10-21 |
2015-04-21 |
Igf Oncology, Llc |
Compounds and methods for treating cancer
|
CA2542834C
(en)
*
|
2003-10-21 |
2012-04-24 |
Igf Oncology, Llc |
Conjugates or co-administration of igf-1 receptor ligands with anti-cancer chemotherapeutic agents
|
BR122018071808B8
(pt)
*
|
2003-11-06 |
2020-06-30 |
Seattle Genetics Inc |
conjugado
|
WO2005072292A2
(en)
*
|
2004-01-24 |
2005-08-11 |
Hugh Mctavish |
Methods for enhancing radiation therapy
|
US20050175619A1
(en)
*
|
2004-02-05 |
2005-08-11 |
Robert Duffy |
Methods of producing antibody conjugates
|
US20050287639A1
(en)
|
2004-05-17 |
2005-12-29 |
California Institute Of Technology |
Methods of incorporating amino acid analogs into proteins
|
JP2008517917A
(ja)
|
2004-10-21 |
2008-05-29 |
アイジーエフ オンコロジー エルエルシー |
癌を治療するための毒素および放射性核種結合igf−1受容体リガンド
|
JP2008521411A
(ja)
|
2004-11-30 |
2008-06-26 |
キュラジェン コーポレイション |
Gpnmbに対する抗体およびその使用
|
US9707302B2
(en)
|
2013-07-23 |
2017-07-18 |
Immunomedics, Inc. |
Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer
|
US10058621B2
(en)
|
2015-06-25 |
2018-08-28 |
Immunomedics, Inc. |
Combination therapy with anti-HLA-DR antibodies and kinase inhibitors in hematopoietic cancers
|
EP1864129B1
(de)
*
|
2005-03-30 |
2010-08-04 |
Saladax Biomedical Inc. |
Doxorubicin-immuntest
|
CN105012953B
(zh)
|
2005-07-25 |
2018-06-22 |
阿普泰沃研发有限责任公司 |
用cd37-特异性和cd20-特异性结合分子减少b-细胞
|
US8052971B2
(en)
*
|
2005-11-21 |
2011-11-08 |
MG Biologics |
Oral use of specific antibodies for intestinal health
|
BRPI0708299A2
(pt)
*
|
2006-02-27 |
2011-05-24 |
Univ Leland Stanford Junior |
composições e métodos para o transporte de moléculas com propriedades melhoradas de liberação através de barreiras biológicas
|
CA2647632C
(en)
|
2006-03-27 |
2017-06-27 |
University Of Maryland Biotechnology Institute |
Glycoprotein synthesis and remodeling by enzymatic transglycosylation
|
PL2099823T5
(pl)
|
2006-12-01 |
2023-02-20 |
Seagen Inc. |
Wariant środków wiążących cel i jego zastosowania
|
WO2008091701A2
(en)
|
2007-01-25 |
2008-07-31 |
Dana-Farber Cancer Institute |
Use of anti-egfr antibodies in treatment of egfr mutant mediated disease
|
WO2008115404A1
(en)
|
2007-03-15 |
2008-09-25 |
Ludwing Institute For Cancer Research |
Treatment method using egfr antibodies and src inhibitors and related formulations
|
CN101802013B
(zh)
|
2007-07-16 |
2014-07-02 |
健泰科生物技术公司 |
人源化抗cd79b抗体和免疫偶联物及使用方法
|
NZ583367A
(en)
|
2007-07-16 |
2012-10-26 |
Genentech Inc |
Anti-cd79b antibodies and immunoconjugates and methods of use
|
CA2696360C
(en)
|
2007-08-14 |
2018-11-20 |
Ludwig Institute For Cancer Research |
Monoclonal antibody targeting the egfr receptor and uses thereof
|
CA2697992C
(en)
|
2007-10-04 |
2017-08-22 |
Zymogenetics, Inc. |
B7 family member zb7h6 and related compositions and methods
|
KR20100107501A
(ko)
|
2008-01-18 |
2010-10-05 |
메디뮨 엘엘씨 |
부위 특이적 접합을 위한 시스테인 조작 항체
|
MX2010008437A
(es)
|
2008-01-31 |
2010-11-25 |
Genentech Inc |
Anticuerpos anti-cd79b e inmunoconjugados y metodos de uso.
|
US8742076B2
(en)
|
2008-02-01 |
2014-06-03 |
Genentech, Inc. |
Nemorubicin metabolite and analog reagents, antibody-drug conjugates and methods
|
US8900589B2
(en)
|
2008-07-15 |
2014-12-02 |
Genetech, Inc. |
Anthracycline derivative conjugates, process for their preparation and their use as antitumor compounds
|
WO2010014236A2
(en)
*
|
2008-07-30 |
2010-02-04 |
The University Of North Carolina At Chapel Hill |
Acylhydrazone-based cleavable linkers
|
CN102802661B
(zh)
|
2009-06-22 |
2016-01-13 |
米迪缪尼有限公司 |
用于位点特异性偶联的工程改造的Fc区
|
WO2011028952A1
(en)
|
2009-09-02 |
2011-03-10 |
Xencor, Inc. |
Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
|
TWI483736B
(zh)
|
2009-10-23 |
2015-05-11 |
Millennium Pharm Inc |
抗-gcc抗體分子及其相關之組合物及方法
|
EP2510011B2
(de)
|
2009-12-09 |
2021-03-31 |
Institut National de la Santé et de la Recherche Médicale |
B7h6 -bindende monoklonale antikörper und ihre verwendung
|
AU2011213609B2
(en)
|
2010-02-08 |
2016-11-03 |
Agensys, Inc. |
Antibody drug conjugates (ADC) that bind to 161P2F10B proteins
|
ES2748347T3
(es)
*
|
2010-03-12 |
2020-03-16 |
Debiopharm Int Sa |
Moléculas de unión a CD37 e inmunoconjugados de las mismas
|
CA2806252C
(en)
|
2010-07-29 |
2019-05-14 |
Xencor, Inc. |
Antibodies with modified isoelectric points
|
TWI764324B
(zh)
|
2010-09-29 |
2022-05-11 |
美商艾澤西公司 |
與191p4d12蛋白結合之抗體藥物共軛物(adc)
|
EP2621954A1
(de)
|
2010-10-01 |
2013-08-07 |
Oxford Biotherapeutics Ltd. |
Anti-rori-antikörper
|
CA2818713C
(en)
|
2010-12-02 |
2019-03-26 |
Nerviano Medical Sciences S.R.L. |
Process for the preparation of morpholinyl anthracycline derivatives
|
KR101993921B1
(ko)
|
2010-12-06 |
2019-06-28 |
시애틀 지네틱스, 인크. |
Liv-1에 대한 인간화 항체 및 이의 암을 치료하기 위한 용도
|
JOP20210044A1
(ar)
|
2010-12-30 |
2017-06-16 |
Takeda Pharmaceuticals Co |
الأجسام المضادة لـ cd38
|
KR20140031883A
(ko)
|
2011-04-01 |
2014-03-13 |
이뮤노젠 아이엔씨 |
Cd37-결합 분자 및 그의 면역콘주게이트
|
HRP20231066T1
(hr)
|
2011-05-27 |
2023-10-27 |
Glaxo Group Limited |
Bcma (cd269/tnfrsf17) - vezujući proteini
|
WO2013022855A1
(en)
|
2011-08-05 |
2013-02-14 |
Xencor, Inc. |
Antibodies with modified isoelectric points and immunofiltering
|
US20130058947A1
(en)
|
2011-09-02 |
2013-03-07 |
Stem Centrx, Inc |
Novel Modulators and Methods of Use
|
AU2012323287B2
(en)
|
2011-10-10 |
2018-02-01 |
Xencor, Inc. |
A method for purifying antibodies
|
US10851178B2
(en)
|
2011-10-10 |
2020-12-01 |
Xencor, Inc. |
Heterodimeric human IgG1 polypeptides with isoelectric point modifications
|
CN109897103A
(zh)
|
2011-11-04 |
2019-06-18 |
酵活有限公司 |
在Fc结构域中具有突变的稳定异源二聚的抗体设计
|
EP2592103A1
(de)
|
2011-11-08 |
2013-05-15 |
Adriacell S.p.A. |
Polymeraldehydderivate
|
CA2859755C
(en)
|
2011-12-23 |
2021-04-20 |
Pfizer Inc. |
Engineered antibody constant regions for site-specific conjugation and methods and uses therefor
|
JP2015505537A
(ja)
|
2012-01-20 |
2015-02-23 |
シー レーン バイオテクノロジーズ, エルエルシー |
結合分子コンジュゲート
|
ES2812849T3
(es)
|
2012-02-24 |
2021-03-18 |
Abbvie Stemcentrx Llc |
Anticuerpos anti-DLL3 y procedimientos de utilización de los mismos
|
AR090549A1
(es)
|
2012-03-30 |
2014-11-19 |
Genentech Inc |
Anticuerpos anti-lgr5 e inmunoconjugados
|
US9816066B2
(en)
|
2012-04-24 |
2017-11-14 |
The Regents Of The University Of California |
Method for delivery of small molecules and proteins across the cell wall of algae using molecular transporters
|
BR112014027166A2
(pt)
|
2012-05-01 |
2017-06-27 |
Genentech Inc |
anticorpo, ácido nucleico, célula hospedeira, método para produzir um anticorpo, imunoconjugado, formulação farmacêutica, método de tratamento, método de inibir proliferação e métodos de detecção.
|
SG11201406252WA
(en)
|
2012-05-15 |
2014-10-30 |
Seattle Genetics Inc |
Self-stabilizing linker conjugates
|
EA201590173A1
(ru)
|
2012-07-09 |
2015-09-30 |
Дженентек, Инк. |
Иммуноконъюгаты, содержащие антитела к cd22
|
CN104411337A
(zh)
|
2012-07-09 |
2015-03-11 |
基因泰克公司 |
包含抗cd79b抗体的免疫偶联物
|
CN112587658A
(zh)
|
2012-07-18 |
2021-04-02 |
博笛生物科技有限公司 |
癌症的靶向免疫治疗
|
US9382329B2
(en)
|
2012-08-14 |
2016-07-05 |
Ibc Pharmaceuticals, Inc. |
Disease therapy by inducing immune response to Trop-2 expressing cells
|
EA201990839A1
(ru)
|
2012-08-23 |
2019-08-30 |
Эдженсис, Инк. |
Конъюгаты антитело-лекарственное средство (adc), которые связываются с белками 158p1d7
|
CA2891280C
(en)
|
2012-11-24 |
2018-03-20 |
Hangzhou Dac Biotech Co., Ltd. |
Hydrophilic linkers and their uses for conjugation of drugs to cell binding molecules
|
US9107960B2
(en)
|
2012-12-13 |
2015-08-18 |
Immunimedics, Inc. |
Antibody-SN-38 immunoconjugates with a CL2A linker
|
US10137196B2
(en)
|
2012-12-13 |
2018-11-27 |
Immunomedics, Inc. |
Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity
|
US10744129B2
(en)
|
2012-12-13 |
2020-08-18 |
Immunomedics, Inc. |
Therapy of small-cell lung cancer (SCLC) with a topoisomerase-I inhibiting antibody-drug conjugate (ADC) targeting Trop-2
|
KR102356017B1
(ko)
|
2012-12-13 |
2022-01-27 |
이뮤노메딕스, 인코오포레이티드 |
개선된 효능 및 감소된 독성을 위한 항체 및 sn-38의 면역컨쥬게이트의 투약
|
US10413539B2
(en)
|
2012-12-13 |
2019-09-17 |
Immunomedics, Inc. |
Therapy for metastatic urothelial cancer with the antibody-drug conjugate, sacituzumab govitecan (IMMU-132)
|
US10206918B2
(en)
|
2012-12-13 |
2019-02-19 |
Immunomedics, Inc. |
Efficacy of anti-HLA-DR antiboddy drug conjugate IMMU-140 (hL243-CL2A-SN-38) in HLA-DR positive cancers
|
US9931417B2
(en)
|
2012-12-13 |
2018-04-03 |
Immunomedics, Inc. |
Antibody-SN-38 immunoconjugates with a CL2A linker
|
US9492566B2
(en)
|
2012-12-13 |
2016-11-15 |
Immunomedics, Inc. |
Antibody-drug conjugates and uses thereof
|
US10968276B2
(en)
|
2013-03-12 |
2021-04-06 |
Xencor, Inc. |
Optimized anti-CD3 variable regions
|
US9605084B2
(en)
|
2013-03-15 |
2017-03-28 |
Xencor, Inc. |
Heterodimeric proteins
|
US11053316B2
(en)
|
2013-01-14 |
2021-07-06 |
Xencor, Inc. |
Optimized antibody variable regions
|
AU2014205086B2
(en)
|
2013-01-14 |
2019-04-18 |
Xencor, Inc. |
Novel heterodimeric proteins
|
US10487155B2
(en)
|
2013-01-14 |
2019-11-26 |
Xencor, Inc. |
Heterodimeric proteins
|
US10131710B2
(en)
|
2013-01-14 |
2018-11-20 |
Xencor, Inc. |
Optimized antibody variable regions
|
US9701759B2
(en)
|
2013-01-14 |
2017-07-11 |
Xencor, Inc. |
Heterodimeric proteins
|
CA2897987A1
(en)
|
2013-01-15 |
2014-07-24 |
Xencor, Inc. |
Rapid clearance of antigen complexes using novel antibodies
|
BR112015019909A2
(pt)
|
2013-02-22 |
2017-08-29 |
Abbvie Stemcentrx Llc |
Conjugados anticorpo-fármaco, composição farmacêutica, usos dos mesmos, e kit
|
US9562099B2
(en)
|
2013-03-14 |
2017-02-07 |
Genentech, Inc. |
Anti-B7-H4 antibodies and immunoconjugates
|
MX2015010777A
(es)
|
2013-03-14 |
2016-04-25 |
Genentech Inc |
Anticuerpos e inmunoconjugados anti-b7-h4.
|
US10519242B2
(en)
|
2013-03-15 |
2019-12-31 |
Xencor, Inc. |
Targeting regulatory T cells with heterodimeric proteins
|
PL3587448T3
(pl)
|
2013-03-15 |
2021-11-29 |
Xencor, Inc. |
Białka heterodimeryczne
|
US10106624B2
(en)
|
2013-03-15 |
2018-10-23 |
Xencor, Inc. |
Heterodimeric proteins
|
AU2014228489B2
(en)
|
2013-03-15 |
2018-11-15 |
Zymeworks Bc Inc. |
Cytotoxic and anti-mitotic compounds, and methods of using the same
|
EP2970486B1
(de)
|
2013-03-15 |
2018-05-16 |
Xencor, Inc. |
Modulation von t-zellen mit bispezifischen antikörpern und fc-fusionen
|
US10858417B2
(en)
|
2013-03-15 |
2020-12-08 |
Xencor, Inc. |
Heterodimeric proteins
|
US11253606B2
(en)
|
2013-07-23 |
2022-02-22 |
Immunomedics, Inc. |
Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, Bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer
|
SG11201600587VA
(en)
|
2013-08-01 |
2016-02-26 |
Agensys Inc |
Antibody drug conjugates (adc) that bind to cd37 proteins
|
CN105792836A
(zh)
|
2013-08-28 |
2016-07-20 |
施特姆森特克斯股份有限公司 |
新型sez6调节剂以及应用方法
|
AU2014312215B2
(en)
|
2013-08-28 |
2020-02-27 |
Abbvie Stemcentrx Llc |
Site-specific antibody conjugation methods and compositions
|
CN105518027A
(zh)
|
2013-09-17 |
2016-04-20 |
豪夫迈·罗氏有限公司 |
使用抗lgr5抗体的方法
|
DK3055331T3
(da)
|
2013-10-11 |
2021-03-22 |
Oxford Bio Therapeutics Ltd |
Konjugerede antistoffer mod ly75 til cancerbehandling
|
JP6502931B2
(ja)
|
2013-10-11 |
2019-04-17 |
アメリカ合衆国 |
Tem8抗体およびその使用
|
EA201690780A1
(ru)
|
2013-10-15 |
2016-08-31 |
Сиэтл Дженетикс, Инк. |
Пегилированные лекарственные средства-линкеры для улучшенной фармакокинетики конъюгатов лиганд-лекарственное средство
|
WO2015061206A2
(en)
|
2013-10-21 |
2015-04-30 |
North Carolina State University |
Methods and constructs for compound delivery
|
EP3066118B1
(de)
|
2013-11-06 |
2020-01-08 |
The U.S.A. as represented by the Secretary, Department of Health and Human Services |
Alk-antikörper, konjugate und chimäre antigenrezeptoren und deren verwendung
|
SG10201710475WA
(en)
|
2013-11-25 |
2018-01-30 |
Seattle Genetics Inc |
Preparing antibodies from cho cell cultures for conjugation
|
WO2015089344A1
(en)
|
2013-12-13 |
2015-06-18 |
Genentech, Inc. |
Anti-cd33 antibodies and immunoconjugates
|
WO2015095223A2
(en)
|
2013-12-16 |
2015-06-25 |
Genentech, Inc. |
Peptidomimetic compounds and antibody-drug conjugates thereof
|
US11560422B2
(en)
|
2013-12-27 |
2023-01-24 |
Zymeworks Inc. |
Sulfonamide-containing linkage systems for drug conjugates
|
WO2015103549A1
(en)
|
2014-01-03 |
2015-07-09 |
The United States Of America, As Represented By The Secretary Department Of Health And Human Services |
Neutralizing antibodies to hiv-1 env and their use
|
CA2936377A1
(en)
|
2014-01-10 |
2015-07-16 |
Shanghai Birdie Biotech, Inc. |
Compounds and compositions for treating egfr expressing tumors
|
JP6835590B2
(ja)
|
2014-01-12 |
2021-02-24 |
アイジーエフ オンコロジー、 エルエルシー |
インスリン様成長因子−1および上皮増殖因子を含む融合タンパク質およびそのバリアントならびにその使用
|
KR20170008202A
(ko)
|
2014-02-21 |
2017-01-23 |
애브비 스템센트알엑스 엘엘씨 |
흑색종에 사용하기 위한 항-dll3 항체 및 약물 접합체
|
ES2960619T3
(es)
|
2014-02-28 |
2024-03-05 |
Hangzhou Dac Biotech Co Ltd |
Enlazadores cargados y sus usos para la conjugación
|
KR20220025946A
(ko)
|
2014-03-21 |
2022-03-03 |
애브비 인코포레이티드 |
항-egfr 항체 및 항체 약물 접합체
|
US10300070B2
(en)
|
2014-03-27 |
2019-05-28 |
The Brigham And Women's Hospital, Inc. |
Metabolically-activated drug conjugates to overcome resistance in cancer therapy
|
RS59907B1
(sr)
|
2014-03-28 |
2020-03-31 |
Xencor Inc |
Bispecifična antitela koja se vezuju za cd38 i cd3
|
RU2016150370A
(ru)
|
2014-05-22 |
2018-06-26 |
Дженентек, Инк. |
Антитела и иммуноконъюгаты против GPC3
|
CN105440135A
(zh)
|
2014-09-01 |
2016-03-30 |
博笛生物科技有限公司 |
用于治疗肿瘤的抗-pd-l1结合物
|
EP3194449A1
(de)
|
2014-07-24 |
2017-07-26 |
Xencor, Inc. |
Schnelle beseitigung von antigenkomplexen unter verwendung neuartiger antikörper
|
JP7085837B2
(ja)
|
2014-09-12 |
2022-06-17 |
ジェネンテック, インコーポレイテッド |
抗her2抗体及び免疫複合体
|
SG11201701128YA
(en)
|
2014-09-12 |
2017-03-30 |
Genentech Inc |
Cysteine engineered antibodies and conjugates
|
CN106714844B
(zh)
*
|
2014-09-12 |
2022-08-05 |
基因泰克公司 |
蒽环类二硫化物中间体、抗体-药物缀合物和方法
|
PE20170670A1
(es)
|
2014-09-12 |
2017-06-06 |
Genentech Inc |
Anticuerpos anti-cll-1 e inmunoconjugados
|
TW201625689A
(zh)
|
2014-09-12 |
2016-07-16 |
建南德克公司 |
抗-b7-h4抗體及免疫結合物
|
IL287645B2
(en)
|
2014-09-17 |
2024-04-01 |
Zymeworks Bc Inc |
Cytotoxic and anti-mitotic compounds and methods for their use
|
LT3262071T
(lt)
|
2014-09-23 |
2020-06-25 |
F. Hoffmann-La Roche Ag |
Anti-cd79b imunokonjugatų naudojimo būdai
|
MX2017006663A
(es)
|
2014-11-19 |
2017-08-21 |
Axon Neuroscience Se |
Anticuerpos tau humanizados en enfermedad de alzheimer.
|
CN116333153A
(zh)
|
2014-11-26 |
2023-06-27 |
森科股份有限公司 |
结合cd3和肿瘤抗原的异二聚体抗体
|
US10259887B2
(en)
|
2014-11-26 |
2019-04-16 |
Xencor, Inc. |
Heterodimeric antibodies that bind CD3 and tumor antigens
|
KR20170084327A
(ko)
|
2014-11-26 |
2017-07-19 |
젠코어 인코포레이티드 |
Cd3 및 cd38에 결합하는 이형이량체 항체
|
US10428155B2
(en)
|
2014-12-22 |
2019-10-01 |
Xencor, Inc. |
Trispecific antibodies
|
WO2016141230A1
(en)
|
2015-03-05 |
2016-09-09 |
Sirenas Llc |
Cyclic peptide analogs and conjugates thereof
|
WO2016141387A1
(en)
|
2015-03-05 |
2016-09-09 |
Xencor, Inc. |
Modulation of t cells with bispecific antibodies and fc fusions
|
EP3268038B1
(de)
|
2015-03-09 |
2021-05-05 |
Agensys, Inc. |
An flt3-proteine bindende antikörper-wirkstoffkonjugate (adc)
|
US10548989B2
(en)
|
2015-04-07 |
2020-02-04 |
Memorial Sloan Kettering Cancer Center |
Nanoparticle immunoconjugates
|
CA2981543A1
(en)
|
2015-04-22 |
2016-10-27 |
Immunomedics, Inc. |
Isolation, detection, diagnosis and/or characterization of circulating trop-2-positive cancer cells
|
EP3091033A1
(de)
|
2015-05-06 |
2016-11-09 |
Gamamabs Pharma |
Anti-human-her3-antikörper und verwendungen davon
|
AU2016276158B2
(en)
|
2015-06-08 |
2022-06-30 |
Debiopharm International, S.A. |
Anti-CD37 immunoconjugate and anti-CD20 antibody combinations
|
CN108603170A
(zh)
|
2015-06-12 |
2018-09-28 |
莱蒂恩技术公司 |
用工程改造的t细胞治疗癌症的方法
|
US10195175B2
(en)
|
2015-06-25 |
2019-02-05 |
Immunomedics, Inc. |
Synergistic effect of anti-Trop-2 antibody-drug conjugate in combination therapy for triple-negative breast cancer when used with microtubule inhibitors or PARP inhibitors
|
PL3316909T3
(pl)
|
2015-06-30 |
2023-11-20 |
Seagen Inc. |
Przeciwciała anty-ntb-a i powiązane kompozycje i sposoby
|
WO2015151081A2
(en)
|
2015-07-12 |
2015-10-08 |
Suzhou M-Conj Biotech Co., Ltd |
Bridge linkers for conjugation of a cell-binding molecule
|
US9839687B2
(en)
|
2015-07-15 |
2017-12-12 |
Suzhou M-Conj Biotech Co., Ltd. |
Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule
|
BR112018003147A2
(pt)
|
2015-08-28 |
2018-09-18 |
Debiopharm International S.A. |
anticorpos e testes para detecção de cd37
|
WO2017044803A1
(en)
|
2015-09-09 |
2017-03-16 |
The United States Of America, As Represented By The Secretary Department Of Health And Human Service |
Expression vector delivery system and use thereof for inducing an immune response
|
CA2997809A1
(en)
|
2015-10-07 |
2017-04-13 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Il-7r-alpha specific antibodies for treating acute lymphoblastic leukemia
|
CA3001306A1
(en)
|
2015-10-09 |
2017-04-13 |
Miltenyi Biotec Technology, Inc. |
Chimeric antigen receptors and methods of use
|
MA43354A
(fr)
|
2015-10-16 |
2018-08-22 |
Genentech Inc |
Conjugués médicamenteux à pont disulfure encombré
|
WO2017066714A1
(en)
|
2015-10-16 |
2017-04-20 |
Compugen Ltd. |
Anti-vsig1 antibodies and drug conjugates
|
US11623957B2
(en)
|
2015-12-07 |
2023-04-11 |
Xencor, Inc. |
Heterodimeric antibodies that bind CD3 and PSMA
|
CN108601841A
(zh)
|
2016-02-10 |
2018-09-28 |
免疫医疗公司 |
Abcg2抑制剂与sacituzumab govitecan(immu-132)的组合克服表达trop-2的癌中对sn-38的抗性
|
US11191821B2
(en)
|
2016-02-27 |
2021-12-07 |
The United States Of America As Represented By The Secretary, Department Of Health And Human Services |
Peptide vaccine formulations and use thereof for inducing an immune response
|
EP3423105B1
(de)
|
2016-03-02 |
2021-05-05 |
Eisai R&D Management Co., Ltd. |
Antikörper-wirkstoff-konjugate auf eribulinbasis und verfahren zur verwendung
|
MA45324A
(fr)
|
2016-03-15 |
2019-01-23 |
Seattle Genetics Inc |
Polythérapie utilisant un adc-liv1 et un agent chimiothérapeutique
|
EP3433278A4
(de)
|
2016-03-25 |
2019-11-06 |
Seattle Genetics, Inc. |
Verfahren zur herstellung von pegylierten wirkstoff-linkern und zwischenprodukten davon
|
JP2019522960A
(ja)
|
2016-04-21 |
2019-08-22 |
アッヴィ・ステムセントルクス・エル・エル・シー |
新規の抗bmpr1b抗体及び使用方法
|
WO2017189483A1
(en)
|
2016-04-25 |
2017-11-02 |
The Johns Hopkins University |
Znt8 assays for drug development and pharmaceutical compositions
|
JP7379795B2
(ja)
|
2016-04-27 |
2023-11-15 |
イミューノメディクス、インコーポレイテッド |
チェックポイント阻害薬に再発/耐性を示す腫瘍を治療するための抗Trop-2-SN-38抗体薬物複合体の効果
|
ES2930255T3
(es)
|
2016-05-13 |
2022-12-09 |
Bioatla Inc |
Anticuerpos anti-Ror2, fragmentos de anticuerpos, sus inmunoconjugados y usos de los mismos
|
WO2017205741A1
(en)
|
2016-05-27 |
2017-11-30 |
Genentech, Inc. |
Bioanalytical method for the characterization of site-specific antibody-drug conjugates
|
WO2017214335A1
(en)
|
2016-06-08 |
2017-12-14 |
Abbvie Inc. |
Anti-b7-h3 antibodies and antibody drug conjugates
|
CN109641962A
(zh)
|
2016-06-08 |
2019-04-16 |
艾伯维公司 |
抗b7-h3抗体和抗体药物偶联物
|
BR112018075630A2
(pt)
|
2016-06-08 |
2019-03-19 |
Abbvie Inc. |
anticorpos anti-cd98 e conjugados de fármaco de anticorpo
|
JP2019522643A
(ja)
|
2016-06-08 |
2019-08-15 |
アッヴィ・インコーポレイテッド |
抗cd98抗体及び抗体薬物コンジュゲート
|
JP2019526529A
(ja)
|
2016-06-08 |
2019-09-19 |
アッヴィ・インコーポレイテッド |
抗b7−h3抗体及び抗体薬物コンジュゲート
|
RU2767357C2
(ru)
|
2016-06-14 |
2022-03-17 |
Ксенкор, Инк. |
Биспецифические антитела-ингибиторы контрольных точек
|
EP3475304B1
(de)
|
2016-06-28 |
2022-03-23 |
Xencor, Inc. |
Somatostatin-rezeptor 2 bindende heterodimere antikörper
|
EP3494139B1
(de)
|
2016-08-05 |
2022-01-12 |
F. Hoffmann-La Roche AG |
Multivalente und multiepitopische anitikörper mit agonistischer wirkung und verfahren zur verwendung
|
US11944689B2
(en)
|
2016-08-09 |
2024-04-02 |
Seagen Inc. |
Drug conjugates with self-stabilizing linkers having improved physiochemical properties
|
US10793632B2
(en)
|
2016-08-30 |
2020-10-06 |
Xencor, Inc. |
Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
|
WO2018045245A1
(en)
|
2016-09-02 |
2018-03-08 |
Sirenas Llc |
Cyclic peptide analogs and conjugates thereof
|
JP7160482B2
(ja)
|
2016-09-02 |
2022-10-25 |
レンティジェン・テクノロジー・インコーポレイテッド |
Duocarを用いてがんを処置するための組成物および方法
|
US10550185B2
(en)
|
2016-10-14 |
2020-02-04 |
Xencor, Inc. |
Bispecific heterodimeric fusion proteins containing IL-15-IL-15Rα Fc-fusion proteins and PD-1 antibody fragments
|
US11278629B2
(en)
|
2016-11-02 |
2022-03-22 |
Debiopharm International, S.A. |
Methods for improving anti-CD37 immunoconjugate therapy
|
KR102459468B1
(ko)
|
2016-11-14 |
2022-10-26 |
항저우 디에이씨 바이오테크 씨오, 엘티디 |
결합 링커, 그러한 결합 링커를 함유하는 세포 결합 분자-약물 결합체, 링커를 갖는 그러한 결합체의 제조 및 사용
|
CN110023334B
(zh)
|
2016-11-21 |
2023-11-14 |
科雅博有限责任公司 |
抗gp73抗体和免疫偶联物
|
JP6706394B1
(ja)
|
2017-01-09 |
2020-06-03 |
レンティジェン・テクノロジー・インコーポレイテッドLentigen Technology, Inc. |
抗メソセリン免疫療法によりがんを処置するための組成物および方法
|
JP2020510432A
(ja)
|
2017-03-02 |
2020-04-09 |
アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル |
Nectin−4への特異性を有する抗体及びその使用
|
GB201703876D0
(en)
|
2017-03-10 |
2017-04-26 |
Berlin-Chemie Ag |
Pharmaceutical combinations
|
WO2018175994A1
(en)
|
2017-03-24 |
2018-09-27 |
Seattle Genetics, Inc. |
Process for the preparation of glucuronide drug-linkers and intermediates thereof
|
AU2018240556A1
(en)
|
2017-03-24 |
2019-10-10 |
Lentigen Technology, Inc. |
Compositions and methods for treating cancer with anti-CD33 immunotherapy
|
EP3600283A4
(de)
|
2017-03-27 |
2020-12-16 |
Immunomedics, Inc. |
Behandlung von trop-2-exprimierendem triple-negativem brustkrebs mit sacituzumab govitecan und einem rad51-hemmer
|
US10799597B2
(en)
|
2017-04-03 |
2020-10-13 |
Immunomedics, Inc. |
Subcutaneous administration of antibody-drug conjugates for cancer therapy
|
BR112019020853A2
(pt)
|
2017-04-04 |
2020-05-12 |
Avidea Technologies, Inc. |
Vacinas à base de peptídeo, métodos de fabricação e usos das mesmas para induzir uma resposta imune
|
CA3056261A1
(en)
|
2017-04-07 |
2018-10-11 |
Juno Therapeutics, Inc. |
Engineered cells expressing prostate-specific membrane antigen (psma) or a modified form thereof and related methods
|
CA3064697A1
(en)
|
2017-04-19 |
2018-10-25 |
Bluefin Biomedicine, Inc. |
Anti-vtcn1 antibodies and antibody drug conjugates
|
KR20200002858A
(ko)
|
2017-04-28 |
2020-01-08 |
아지노모토 가부시키가이샤 |
가용성 단백질에 대한 친화성 물질, 절단성 부분 및 반응성기를 갖는 화합물 또는 이의 염
|
CN110636867B
(zh)
|
2017-05-21 |
2023-09-05 |
Igf肿瘤公司 |
胰岛素样生长因子——用于治疗骨髓增生异常综合症的化学治疗缀合物
|
WO2019006472A1
(en)
|
2017-06-30 |
2019-01-03 |
Xencor, Inc. |
TARGETED HETETRODIMERIC FUSION PROTEINS CONTAINING IL-15 / IL-15RA AND ANTIGEN-BINDING DOMAINS
|
EP3652540A4
(de)
|
2017-07-12 |
2021-04-07 |
The Johns Hopkins University |
Auf proteoliposom basierendes znt-8-selbstantigen zur diagnose von typ-1-diabetes
|
CA3071624A1
(en)
|
2017-07-31 |
2019-02-07 |
Lentigen Technology, Inc. |
Compositions and methods for treating cancer with anti-cd19/cd20 immunotherapy
|
EP3668600A1
(de)
|
2017-08-10 |
2020-06-24 |
Abionyx Pharma SA |
Cargomere
|
ES2960419T3
(es)
|
2017-09-15 |
2024-03-04 |
Lentigen Tech Inc |
Composiciones y métodos de tratamiento de cáncer con inmunoterapia anti-CD19
|
WO2019079249A1
(en)
|
2017-10-16 |
2019-04-25 |
Lentigen Technology, Inc. |
COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER WITH ANTI-CD22 IMMUNOTHERAPY
|
CN111542344A
(zh)
|
2017-10-23 |
2020-08-14 |
马布林克生物科学公司 |
包含单分子量聚肌氨酸的配体-药物-缀合物
|
US10981992B2
(en)
|
2017-11-08 |
2021-04-20 |
Xencor, Inc. |
Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
|
CA3082383A1
(en)
|
2017-11-08 |
2019-05-16 |
Xencor, Inc. |
Bispecific and monospecific antibodies using novel anti-pd-1 sequences
|
JP2021505540A
(ja)
|
2017-12-01 |
2021-02-18 |
シアトル ジェネティクス インコーポレーテッド |
乳がんの処置のためのヒト化抗liv1抗体
|
EP3717515A2
(de)
|
2017-12-01 |
2020-10-07 |
Seattle Genetics, Inc. |
Cd47 (maskierte)-antikörper und deren verwendung zur behandlung von krebs
|
CN111655718A
(zh)
|
2017-12-19 |
2020-09-11 |
Xencor股份有限公司 |
经过工程化的il-2 fc融合蛋白
|
JP7377802B2
(ja)
|
2017-12-20 |
2023-11-10 |
レンティジェン・テクノロジー・インコーポレイテッド |
免疫療法を用いてhiv/aidsを処置するための組成物および方法
|
WO2019180150A1
(en)
|
2018-03-22 |
2019-09-26 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for modulating innate lymphoid cell activity, antibody drug conjugates and uses in therapy
|
TW202003047A
(zh)
|
2018-03-23 |
2020-01-16 |
美商西雅圖遺傳學公司 |
包括微管蛋白破壞劑之抗體藥物結合物治療實體腫瘤之用途
|
SG11202008098TA
(en)
|
2018-03-28 |
2020-10-29 |
Axon Neuroscience Se |
Antibody-based methods of detecting and treating alzheimer's disease
|
US10982006B2
(en)
|
2018-04-04 |
2021-04-20 |
Xencor, Inc. |
Heterodimeric antibodies that bind fibroblast activation protein
|
WO2019204655A1
(en)
|
2018-04-18 |
2019-10-24 |
Xencor, Inc. |
Tim-3 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and tim-3 antigen binding domains
|
JP2021521784A
(ja)
|
2018-04-18 |
2021-08-30 |
ゼンコア インコーポレイテッド |
IL−15/IL−15RaFc融合タンパク質とPD−1抗原結合ドメインを含むPD−1標的化ヘテロダイマー融合タンパク質およびそれらの使用
|
AU2019272844A1
(en)
|
2018-05-22 |
2021-01-21 |
Barinthus Biotherapeutics North America, Inc. |
Improved methods of manufacturing peptide-based vaccines
|
JOP20200268A1
(ar)
|
2018-06-01 |
2020-10-26 |
Eisai R&D Man Co Ltd |
تضفير مترافقات عقار جسم مضاد معدل وطرق استخدامها
|
CN112261954A
(zh)
|
2018-06-14 |
2021-01-22 |
味之素株式会社 |
具有针对抗体的亲和性物质和生物正交性官能团的化合物或其盐
|
KR20210020901A
(ko)
|
2018-06-14 |
2021-02-24 |
아지노모토 가부시키가이샤 |
항체에 대한 친화성 물질, 절단성 부분 및 반응성기를 갖는 화합물 또는 이의 염
|
GB201809746D0
(en)
|
2018-06-14 |
2018-08-01 |
Berlin Chemie Ag |
Pharmaceutical combinations
|
JOP20200343A1
(ar)
|
2018-07-02 |
2020-12-31 |
Xencor Inc |
بروتين ربط مولد ضد مضاد لـ steap1
|
AU2019343184A1
(en)
|
2018-09-20 |
2021-04-15 |
Lentigen Technology, Inc. |
Compositions and methods for treating cancer with anti-CD123 immunotherapy
|
JP2022502043A
(ja)
|
2018-09-26 |
2022-01-11 |
レンティジェン・テクノロジー・インコーポレイテッドLentigen Technology, Inc. |
抗cd19/cd22免疫療法によりがんを処置するための組成物および方法
|
SG11202103192RA
(en)
|
2018-10-03 |
2021-04-29 |
Xencor Inc |
Il-12 heterodimeric fc-fusion proteins
|
EP3860646A1
(de)
|
2018-10-03 |
2021-08-11 |
Avidea Technologies, Inc. |
Aromatische ringsubstituierte amphiphile polymere als wirkstoffabgabesysteme
|
CN113227124A
(zh)
|
2018-10-31 |
2021-08-06 |
味之素株式会社 |
具有针对抗体的亲和性物质、切割性部分及反应性基团的化合物或其盐
|
CN113412119A
(zh)
|
2018-11-30 |
2021-09-17 |
莱蒂恩技术公司 |
用于用抗cd38免疫治疗来治疗癌症的组合物和方法
|
TW202039007A
(zh)
|
2018-12-13 |
2020-11-01 |
日商衛材R&D企管股份有限公司 |
荷伯希二烯(herboxidiene)剪接調節抗體-藥物結合物及其使用方法
|
US20220088204A1
(en)
*
|
2019-01-25 |
2022-03-24 |
Yale University |
Anticancer drugs and methods of making and using same
|
AU2020219732A1
(en)
|
2019-02-05 |
2021-08-05 |
Seagen Inc. |
Anti-CD228 antibodies and antibody-drug conjugates
|
KR20210134725A
(ko)
|
2019-03-01 |
2021-11-10 |
젠코어 인코포레이티드 |
Enpp3과 cd3에 결합하는 이종이량체 항체
|
JP2022524507A
(ja)
|
2019-03-06 |
2022-05-06 |
レンティジェン・テクノロジー・インコーポレイテッド |
自己駆動型キメラ抗原受容体を用いてがんを処置するための組成物および方法
|
KR20210154158A
(ko)
|
2019-03-20 |
2021-12-20 |
더 리전트 오브 더 유니버시티 오브 캘리포니아 |
클라우딘-6 항체 및 약물 컨쥬게이트
|
KR20220025705A
(ko)
|
2019-04-17 |
2022-03-03 |
아비디아 테크놀로지스, 인크. |
리간드 디스플레이 및/또는 약물 전달을 위한 성상 중합체의 조성물 및 제조 방법
|
EP3958908A1
(de)
|
2019-04-24 |
2022-03-02 |
Heidelberg Pharma Research GmbH |
Amatoxin-antikörper-wirkstoff-konjugate und verwendungen davon
|
CA3140102A1
(en)
|
2019-05-30 |
2020-12-03 |
Dina SCHNEIDER |
Compositions and methods for treating cancer with anti-bcma immunotherapy
|
TW202112354A
(zh)
|
2019-06-05 |
2021-04-01 |
美商西雅圖遺傳學公司 |
遮蔽抗體調配物
|
US20220306727A1
(en)
|
2019-06-05 |
2022-09-29 |
Seagen Inc. |
Methods of Purifying Masked Antibodies
|
AU2020299382A1
(en)
|
2019-07-02 |
2022-01-20 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Monoclonal antibodies that bind EGFRvIII and their use
|
WO2021016233A1
(en)
|
2019-07-22 |
2021-01-28 |
Seagen Inc. |
Humanized anti-liv1 antibodies for the treatment of cancer
|
KR20220079590A
(ko)
|
2019-10-04 |
2022-06-13 |
티에이이 라이프 사이언시스 |
Fc 돌연변이 및 부위-특이적인 접합 성질을 포함하는 항체 조성물
|
AR120147A1
(es)
|
2019-10-04 |
2022-02-02 |
Seattle Genetics Inc |
Anticuerpos anti-pd-l1 y conjugados anticuerpo-fármaco
|
EP3812008A1
(de)
|
2019-10-23 |
2021-04-28 |
Gamamabs Pharma |
Amh-kompetitiver antagonistischer antikörper
|
WO2021116119A1
(en)
|
2019-12-09 |
2021-06-17 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Antibodies having specificity to her4 and uses thereof
|
CA3164037A1
(en)
|
2020-01-08 |
2021-07-15 |
Synthis Therapeutics, Inc. |
Alk5 inhibitor conjugates and uses thereof
|
WO2021224186A1
(en)
|
2020-05-04 |
2021-11-11 |
Institut Curie |
New pyridine derivatives as radiosensitizers
|
WO2021228956A1
(en)
|
2020-05-12 |
2021-11-18 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
New method to treat cutaneous t-cell lymphomas and tfh derived lymphomas
|
WO2021231976A1
(en)
|
2020-05-14 |
2021-11-18 |
Xencor, Inc. |
Heterodimeric antibodies that bind prostate specific membrane antigen (psma) and cd3
|
AR122546A1
(es)
|
2020-06-05 |
2022-09-21 |
Eisai R&D Man Co Ltd |
Conjugados de anticuerpo anti bcma-fármaco y métodos de uso
|
WO2021251358A1
(ja)
|
2020-06-09 |
2021-12-16 |
味の素株式会社 |
修飾フェリチンおよびその製造方法
|
US11497770B2
(en)
|
2020-06-22 |
2022-11-15 |
Lentigen Technology, Inc. |
Compositions and methods for treating cancer with TSLPR-CD19 or TSLPR-CD22 immunotherapy
|
CA3189225A1
(en)
|
2020-08-04 |
2022-02-10 |
Seagen Inc. |
Anti-cd228 antibodies and antibody-drug conjugates
|
EP3970752A1
(de)
|
2020-09-17 |
2022-03-23 |
Merck Patent GmbH |
Moleküle mit löslichkeitsmarkierung und zugehörige verfahren
|
WO2022066635A1
(en)
|
2020-09-22 |
2022-03-31 |
Avidea Technologies, Inc. |
Compositions and methods of manufacturing amphiphilic block copolymers that form nanoparticles in situ
|
CA3197158A1
(en)
|
2020-09-28 |
2022-03-31 |
Seagen Inc. |
Humanized anti-liv1 antibodies for the treatment of cancer
|
AU2021354095A1
(en)
|
2020-10-01 |
2023-06-08 |
Abionyx Pharma Sa |
Compositions comprising lipid binding protein-based complexes for use for treating eye diseases
|
WO2022086853A1
(en)
|
2020-10-19 |
2022-04-28 |
Avidea Technologies, Inc. |
Star polymer drug conjugates
|
EP4232453A1
(de)
|
2020-10-20 |
2023-08-30 |
Institut Curie |
Metallische trans-(n-heterocyclische carben)-amin-platin-komplexe und verwendungen davon zur behandlung von krebs
|
CA3171093A1
(en)
|
2020-11-05 |
2022-05-12 |
Dina SCHNEIDER |
Compositions and methods for treating cancer with anti-cd19/cd22 immunotherapy
|
JPWO2022154127A1
(de)
|
2021-01-18 |
2022-07-21 |
|
|
KR20230133294A
(ko)
|
2021-01-18 |
2023-09-19 |
아지노모토 가부시키가이샤 |
화합물 또는 그 염, 및 그것들에 의해 얻어지는 항체
|
UY39610A
(es)
|
2021-01-20 |
2022-08-31 |
Abbvie Inc |
Conjugados anticuerpo-fármaco anti-egfr
|
IL305736A
(en)
|
2021-03-09 |
2023-11-01 |
Xencor Inc |
Heterodimeric antibodies that bind CD3 and CLDN6
|
EP4305065A1
(de)
|
2021-03-10 |
2024-01-17 |
Xencor, Inc. |
Cd3 und gpc3 bindende heterodimere antikörper
|
CN116964076A
(zh)
|
2021-03-11 |
2023-10-27 |
味之素株式会社 |
化合物或其盐、以及由它们得到的抗体
|
WO2022189618A1
(en)
|
2021-03-12 |
2022-09-15 |
Institut Curie |
Nitrogen-containing heterocycles as radiosensitizers
|
EP4310096A1
(de)
|
2021-03-16 |
2024-01-24 |
Ajinomoto Co., Inc. |
Komplex oder salz davon und verfahren zur herstellung davon
|
BR112023018189A2
(pt)
|
2021-03-19 |
2023-10-24 |
Heidelberg Pharma Res Gmbh |
Conjugados de anticorpos de amatoxina específicos de linfócitos b, composição famacêutica e uso relacionados
|
CA3213985A1
(en)
|
2021-03-30 |
2022-10-06 |
Chang Sik Park |
Antibody-drug conjugate including antibody against human cldn18.2, and use thereof
|
EP4319820A1
(de)
|
2021-04-10 |
2024-02-14 |
Profoundbio Us Co. |
Folr1-bindende wirkstoffe, konjugate davon und verfahren zur verwendung davon
|
JP2024514154A
(ja)
|
2021-04-15 |
2024-03-28 |
アビオニクス ファーマ エスエー |
臓器保存溶液における脂質結合タンパク質ベースの複合体の使用
|
WO2022226317A1
(en)
|
2021-04-23 |
2022-10-27 |
Profoundbio Us Co. |
Anti-cd70 antibodies, conjugates thereof and methods of using the same
|
TW202320857A
(zh)
|
2021-07-06 |
2023-06-01 |
美商普方生物製藥美國公司 |
連接子、藥物連接子及其結合物及其使用方法
|
WO2023288236A1
(en)
|
2021-07-14 |
2023-01-19 |
Seagen Inc. |
Antibody masking domains
|
WO2023049825A1
(en)
|
2021-09-24 |
2023-03-30 |
Seagen Inc. |
Improved antibody masking domains
|
CA3234692A1
(en)
|
2021-09-30 |
2023-04-06 |
Ajinomoto Co., Inc. |
Conjugate of antibody and functional substance or salt thereof, and antibody derivative and compound used in production of the same or salts thereof
|
WO2023089314A1
(en)
|
2021-11-18 |
2023-05-25 |
Oxford Biotherapeutics Limited |
Pharmaceutical combinations
|
WO2023092099A1
(en)
|
2021-11-19 |
2023-05-25 |
Ardeagen Corporation |
Gpc3 binding agents, conjugates thereof and methods of using the same
|
US11590169B1
(en)
|
2022-03-02 |
2023-02-28 |
Lentigen Technology, Inc. |
Compositions and methods for treating cancer with anti-CD123 immunotherapy
|
US20230338424A1
(en)
|
2022-03-02 |
2023-10-26 |
Lentigen Technology, Inc. |
Compositions and Methods for Treating Cancer with Anti-CD123 Immunotherapy
|
WO2023169896A1
(en)
|
2022-03-09 |
2023-09-14 |
Astrazeneca Ab |
BINDING MOLECULES AGAINST FRα
|
WO2023170216A1
(en)
|
2022-03-11 |
2023-09-14 |
Astrazeneca Ab |
A SCORING METHOD FOR AN ANTI-FRα ANTIBODY-DRUG CONJUGATE THERAPY
|
WO2023194797A1
(en)
|
2022-04-06 |
2023-10-12 |
Abionyx Pharma Sa |
Methods for treating eye diseases using lipid binding protein-based complexes
|
US20230355792A1
(en)
|
2022-04-07 |
2023-11-09 |
Heidelberg Pharma Research Gmbh |
Methods of improving the therapeutic index
|
WO2024026107A2
(en)
|
2022-07-28 |
2024-02-01 |
Lentigen Technology, Inc. |
Chimeric antigen receptor therapies for treating solid tumors
|
US20240075142A1
(en)
|
2022-08-26 |
2024-03-07 |
Lentigen Technology, Inc. |
Compositions and Methods for Treating Cancer with Fully Human Anti-CD20/CD19 Immunotherapy
|
WO2024052503A1
(en)
|
2022-09-08 |
2024-03-14 |
Institut National de la Santé et de la Recherche Médicale |
Antibodies having specificity to ltbp2 and uses thereof
|
WO2024064714A2
(en)
|
2022-09-21 |
2024-03-28 |
Seagen Inc. |
Antibodies that bind cd228
|